<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17948</article-id><article-id pub-id-type="doi">10.15789/2220-7619-HPI-17948</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hematological parameters in hepatocellular carcinoma AND microRNA-223 gene associated with Hepatitis virus in local area</article-title><trans-title-group xml:lang="ru"><trans-title>Гематологические показатели при гепатоцеллюлярной карциноме и ген микроРНК-223, ассоциированный с локальным вирусом гепатита</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Al-Janaby</surname><given-names>M. S.</given-names></name><name xml:lang="ru"><surname>Аль-Джанаби</surname><given-names>М. С.</given-names></name></name-alternatives><address><country country="IQ">Iraq</country></address><bio xml:lang="en"><p>PhD, доцент кафедры биотехнологии, факультет естественных наук</p></bio><bio xml:lang="ru"><p>PhD, Assistant Professor, Department of Biotechnology</p></bio><email>rana2011@uoanbar.edu.iq</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Abdujaleel</surname><given-names>R. H.</given-names></name><name xml:lang="ru"><surname>Абуджалил</surname><given-names>Р. Х.</given-names></name></name-alternatives><address><country country="IQ">Iraq</country></address><bio xml:lang="en"><p>PhD, Lecturer, Department of Biotechnology</p></bio><bio xml:lang="ru"><p>PhD, преподаватель кафедры биотехнологии, факультет естественных наук</p></bio><email>rana2011@uoanbar.edu.iq</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Najm</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Нажм</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="IQ">Iraq</country></address><bio xml:lang="en"><p>PhD, Assistant Professor, Department of Pharmacology</p></bio><bio xml:lang="ru"><p>PhD, доцент кафедры фармакологии, медицинский факультет</p></bio><email>rana2011@uoanbar.edu.iq</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mohsen</surname><given-names>Rana Talib</given-names></name><name xml:lang="ru"><surname>Мохсен</surname><given-names>Рана Талиб</given-names></name></name-alternatives><address><country country="IQ">Iraq</country></address><bio xml:lang="en"><p>PhD, Assistant Professor, Department of Biotechnology</p></bio><bio xml:lang="ru"><p>PhD, доцент кафедры биотехнологии, факультет естественных наук</p></bio><email>rana2011@uoanbar.edu.iq</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alalwani</surname><given-names>A. K.</given-names></name><name xml:lang="ru"><surname>Алавани</surname><given-names>А. К.</given-names></name></name-alternatives><address><country country="IQ">Iraq</country></address><bio xml:lang="en"><p>Assistant Lecturer, Department of Biotechnology</p></bio><bio xml:lang="ru"><p>ассистент преподавателя кафедры биотехнологии, факультет естественных наук</p></bio><email>rana2011@uoanbar.edu.iq</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">College of Science, University of Anbar</institution></aff><aff><institution xml:lang="ru">Университет Анбар</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">College of Medicine, Ibn Sina University of Medical and Pharmaceutical Sciences</institution></aff><aff><institution xml:lang="ru">Университет медицинских и фармацевтических наук имени Ибн Сины</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-08-11" publication-format="electronic"><day>11</day><month>08</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-12-24" publication-format="electronic"><day>24</day><month>12</month><year>2025</year></pub-date><volume>15</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>1137</fpage><lpage>1142</lpage><history><date date-type="received" iso-8601-date="2025-06-19"><day>19</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-08-07"><day>07</day><month>08</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Al-Janaby M.S., Abdujaleel R.H., Najm M.A., Mohsen R.T., Alalwani A.K.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Аль-Джанаби М.С., Абуджалил Р.Х., Нажм М.А., Мохсен Р.Т., Алавани А.К.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Al-Janaby M.S., Abdujaleel R.H., Najm M.A., Mohsen R.T., Alalwani A.K.</copyright-holder><copyright-holder xml:lang="ru">Аль-Джанаби М.С., Абуджалил Р.Х., Нажм М.А., Мохсен Р.Т., Алавани А.К.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/17948">https://iimmun.ru/iimm/article/view/17948</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>Hepatocyte function may be altered by chronic HBV and HCV infections through similar mechanisms that influence the onset of hepatocellular cancer. This current work points to examine the function of microRNA-223 in Iraqi hepatocellular carcinoma (HCC) patients induced by hepatitis virus. MicroRNA-223 served as calibrator to explores its evaluate disease progression and diagnosis. <bold>Materials and methods.</bold> Blood samples were then drawn from 20 people (males and females and different ages), some of them were latterly diagnosed with HCC. these blood samples were used later for molecular study to find target gene expression. <bold>Results. </bold>The importance of HCV, HBV, and liver cancer was examined in this study, along with the drop in research and studies conducted in Iraq. Those who got treatment had somewhat higher levels of microRNA-223 countenance, whereas those who were diagnosed early and did not get treatment had lower levels. MicroRNA-223 appearance stages were meaningfully lower in the first phase of hepatitis samples than in standard samples (p &lt; 0.0001), which may indicate that microRNA-223 can be used as a biomarker to monitor conduct effectiveness. It is recommended that more research done in this area to help in diagnosis. <bold>Conclusion.</bold> MicroRNAs are an essential tool for early diagnosis and for monitoring the onset and progression of disease due to their great specificity and reliability. all results hat HCC patients with HBV and HCV expressed miR-223 at lower levels than healthy controls. Some hematological and parameters differed significantly from those in the control group.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Функция гепатоцитов может изменяться при хронических инфекциях, вызванных вирусами гепатита В и С, посредством сходных механизмов, ведущих к развитию гепатоцеллюлярного рака. Целью настоящей работы было изучение функции микроРНК-223 у иракских пациентов с гепатоцеллюлярной карциномой (ГЦК), вызванной вирусом гепатита С. МикроРНК-223 служила калибратором для оценки прогрессирования заболевания и диагностики. <bold>Материалы и методы.</bold> Образцы крови были получены от 20 человек (мужчин и женщин разного возраста), у некоторых из них впоследствии была диагностирована ГЦК. Образцы крови были в дальнейшем использованы для молекулярного анализа экспрессии целевых генов. <bold>Результаты.</bold> В данном исследовании изучалась ассоциации между обнаружением вирусов гепатита С и В и раком печени, а также сокращение количества исследований в этой области, проводимых в Ираке. У тех, кто получал лечение, уровень микроРНК-223 был несколько выше, тогда как у лиц, кому диагноз был поставлен на ранней стадии, и кто не получал лечения, уровень был ниже. Уровень экспрессии микроРНК-223 в образцах первой фазы гепатита был значительно ниже, чем в контрольных образцах (p &lt; 0,0001), что может указывать на возможность использования микроРНК-223 в качестве биомаркера для мониторинга эффективности лечения. Рекомендуется проведение дополнительных исследований в этой области для повышения эффективности диагностики. <bold>Заключение. </bold>Разные микроРНК являются важным инструментом ранней диагностики и мониторинга начала и прогрессирования заболевания благодаря своей высокой специфичности и надежности. Полученные результаты свидетельствуют о том, что у пациентов с ГЦК при гепатите B и гепатите C экспрессия miR-223 была ниже, чем у здоровых лиц контрольной группы. Ряд гематологических показателей и параметров достоверно отличались у пациентов от таковых в контрольной группе.</p></trans-abstract><kwd-group xml:lang="en"><kwd>microRNA-223</kwd><kwd>hepatocellular carcinoma</kwd><kwd>expression</kwd><kwd>hepatitis B</kwd><kwd>hepatitis C</kwd><kwd>biomarkers</kwd><kwd>Iraqi patients</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>микроРНК-223</kwd><kwd>гепатоцеллюлярная карцинома</kwd><kwd>экспрессия</kwd><kwd>гепатит B</kwd><kwd>гепатит C</kwd><kwd>биомаркеры</kwd><kwd>иракские пациенты</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Abosaooda M., Bahir H., Ali Salman N., Kamil Abbood S., Yassen Qassem L., Kadhim Jassem I.A., Ayyed Najm M., Soleymanabadi H. Evaluate the potential utilisation of B3S monolayer as a novel formaldehyde gas sensor. Mol. Phys., 2023, vol. 122, no. 12: e2294154. doi: 10.1080/00268976.2023.2294154</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Calin G.A., Croce C.M. MicroRNA signatures in human cancer. Nat. Rev. Cancer, 2006, vol. 6, no. 11, pp. 857–866. doi: 10.1038/nrc1997</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cione E., Abrego Guandique D.M., Caroleo M.C., Luciani F., Colosimo M., Cannataro R. Liver damage and microRNAs: An Update. Curr. Issues Mol. Biol., 2023, vol. 45, no. 1, pp. 78–91. doi: 10.3390/cimb45010006</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Daghman B., Kaddar N., Najm M.A., Barakat H. Comparison of double dose of Paracetamol tablets 500mg with one Paracetamol tablet 1000mg. Res. J. Pharm. Technol., 2024, vol. 17, no. 10, pp. 4671–4676. doi: 10.52711/0974-360X.2024.00720</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Dong Y.W., Wang R., Cai Q.Q., Qi B., Wu W., Zhang Y.H., Wu X.Z. Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells. J. Hepatol., 2014, vol. 60, no. 4, pp. 792–801. doi: 10.1016/j.jhep.2013.12.004</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Fanning G.C., Zoulim F., Hou J., Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug Discov., 2019, vol. 18, no. 11, pp. 827–844. doi: 10.1038/s41573-019-0037-0</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Faramin Lashkarian M., Hashemipour N., Niaraki N., Soghala S., Moradi A., Sarhangi S., Hatami M., Aghaei-Zarch F., Khosravifar M., Mohammadzadeh A., Najafi S., Majidpoor J., Farnia P., Aghaei-Zarch S.M. MicroRNA-122 in human cancers: from mechanistic to clinical perspectives. Cancer Cell Int., 2023, vol. 23, no. 1: 29. doi: 10.1186/s12935-023-02868-z</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gu J., Xu H., Chen Y., Li N., Hou X. MiR-223 as a Regulator and Therapeutic Target in Liver Diseases. Front. Immunol., 2022, vol. 13: 860661. doi: 10.3389/fimmu.2022.860661</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hassan S., Mohsen R.T., Farman S. Interleukin-37 gene single nucleotide polymorphisms and patient susceptibility to hepatitis B and C infection. Opera Med. Physiol., 2024, vol. 11, no. 1, pp. 52–60. doi: 10.24412/2500-2295-2024-1-52-60</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hussein M.U., Mohsen R.T. Ambient Decontamination by Non-Thermal Plasma in Atmospheric Pressure Air. J. Phys.: Conf. Ser., 2017, vol. 1032, no. 1: 012032. doi: 10.1088/1742-6596/1032/1/012032</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin., 2011, vol. 61, no. 2, pp. 69–90. doi: 10.3322/caac.20107</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kennedy K., Graham S.M., Arora N., Shuhart M.C., Kim H.N. Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis. PLoS One, 2018, vol. 13, no. 9: e0204031. doi: 10.1371/journal.pone.0204031</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kisseleva T., Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol., 2021, vol. 18, no. 3, pp. 151–166. doi: 10.1038/s41575-020-00372-7</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Mohsen R.T., Al-Azzawi R.H., Ad’hiah A.H. Hepatitis B virus genotypes among chronic hepatitis B patients from Baghdad Iraq and their impact on liver function. Gene Rep., 2019, vol. 17: 100548. doi: 10.1016/j.genrep.2019.100548</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Mohsen R.T., Al-Azzawi R.H., Adhiah A.H. Serum level of interleukin-35 in patients with chronic hepatitis B virus infection. Iraqi J. Sci., 2020, vol. 61, no. 11, pp. 2860–2865. doi: 10.24996/ijs.2020.61.11.9</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mohsen R.T., Al-Azzawi R.H., Adhiah A.H. Single-nucleotide polymorphism of IL12A gene (rs582537 A/C/G) and susceptibility to chronic hepatitis B virus infection among Iraqi patients. Egypt. J. Med. Hum. Genet., 2022, vol. 23, no. 1: 1-3. doi: 10.1186/s43042-022-00322-9</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Mohsen R., Al-Taee Z., Hussien Habeeb W., Abd-Alazeez R., Hassan S., Mohsen S. microRNA-122 gene expression in Iraqi patients with hepatocellular carcinoma. Asia-Pac. J. Mol. Biol. Biotechnol., 2024, vol. 32, no. 4, pp. 245–250. doi: 10.35118/apjmbb.2024.032.4.25</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Mohsen R., Khudhair I., Alkubaisi M., Al-Taee Z., Hussien Habeeb W., Hassan S. Hepatitis virus-related microRNA-122 gene and biochemical parameters in Iraqi patients with hepatocellular carcinoma. Egypt. J. Med. Microbiol., 2025, vol. 34, no. 1, pp. 141–148. doi: 10.21608/ejmm.2024.317083.1324</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Nasir G., Najm M., Mahmood H. Association Between Silver Nanoparticle Dose and Brain or Renal NF-κB Gene Expression. J. Nanostruct., 2025, vol. 15, no. 1, pp. 249–254. doi: 10.22052/JNS.2025.01.024</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Nasir G.A., Khudhair I.A., Najm M.A., Mahmood H.M. Nanotechnology at the Molecular Level. Al-Rafidain J. Med. Sci., 2022, vol. 3, pp. 71–74. doi: 10.54133/ajms.v3i.88</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Ogunwobi O.O., Harricharran T., Huaman J., Galuza A., Odumuwagun O., Tan Y., Nguyen M.T. Mechanisms of hepatocellular carcinoma progression. World J. Gastroenterol., 2019, vol. 25, no. 19, pp. 2279–2293. doi: 10.3748/wjg.v25.i19.2279</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ormancey M., Thuleau P., Combier J.P., Plaza S. The Essentials on microRNA-Encoded Peptides from Plants to Animals. Biomolecules, 2023, vol. 13, no. 2: 206. doi: 10.3390/biom13020206</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ryerson A.B., Schillie S., Barker L.K., Kupronis B.A., Wester C. Vital signs: newly reported acute and chronic hepatitis C Cases —United States, 2009–2018. Morb. Mortal. Wkly Rep., 2020, vol. 69, no. 14: 399.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Sartorius K., Makarova J., Sartorius B., An P., Winkler C., Chuturgoon A., Kramvis A. The regulatory role of microRNA in hepatitis-B virus-associated hepatocellular carcinoma (HBV-HCC) pathogenesis. Cells, 2019, vol. 8, no. 12: 1504. doi: 10.3390/cells8121504</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tarocchi M., Polvani S., Marroncini G., Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J. Gastroenterol., 2014, vol. 20, no. 33, pp. 11630–11640. doi: 10.3748/wjg.v20.i33.11630</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Wong Q.W., Lung R.W., Law P.T., Lai P.B., Chan K.Y., To K.F., Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology, 2008, vol. 135, no. 1, pp. 257–269. doi: 10.1053/ j.gastro.2008.04.003</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Xiaoyue L., Shujie L., Yongxiang Y. Research progress in hepatocellular carcinoma associated with hepatitis B virus and hepatitis C virus. Electron. J. Emerg. Infect. Dis., 2022, vol. 7, no. 1: 92.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ye D., Zhang T., Lou G., Liu Y. Role of miR-223 in the pathophysiology of liver diseases. Exp. Mol. Med., 2018, vol. 50, no. 9, pp. 1–12. doi: 10.1038/s12276-018-0153-7</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Yuan S., Wu Q., Wang Z., Che Y., Zheng S., Chen Y., Shi F. miR-223: An immune regulator in infectious disorders. Front. Immunol., 2021, vol. 12: 781815. doi: 10.3389/fimmu.2021.781815</mixed-citation></ref></ref-list></back></article>
